Breakthrough AI for Hemodynamics and Hypertension Added to Exo Iris®

SANTA CLARA, Calif.--(BUSINESS WIRE)--Exo (pronounced “echo”), the leader in accessible medical imaging, unveils its latest SweepAI™ advancements for Exo Iris®. With new capabilities for automatically quantifying IVC collapsibility and myocardial wall thickness, clinicians now get objective data in seconds to help assess fluid status and heart health.

By adding SweepAI-based IVC collapsibility analysis to Exo’s cardiac and lung AI, providers can now rapidly pinpoint causes of shortness of breath and determine fluid tolerance.

With nearly half of U.S. adults facing high blood pressure, according to the Centers for Disease Control and Prevention (CDC), Exo’s SweepAI™ now assesses the heart’s Posterior and Interventricular Septal wall thickness, providing critical insights into the impact of chronic hypertension.

Patient fluid management is critical in multiple settings, including emergency departments, hospitals, and surgeries. Mismanagement can lead to major complications, lengthen hospital stays, and increase unnecessary hospital costs.

“Determination of a patient’s fluid status is a constant discussion in the ED, ICU, and medical floors. Leveraging Exo’s cardiac, lung and now IVC AI is a game changer. It gives clinicians confidence when imaging these 3 distinct organs so that optimal care can be performed right at the bedside,” said Arun Nagdev, M.D., VP of Clinical Programs at Exo.

“The speed of Exo’s innovation in ultrasound is remarkable. We are constantly pushing boundaries to benefit clinicians and patients,” said Sandeep Akkaraju, CEO of Exo.

Exo’s AI runs on-edge—no Wi-Fi required—and features enhanced imaging with intuitive adjustments. Visit Exo’s website to explore these capabilities.

About Exo

Exo is redefining medical imaging with its high-performance ultrasound platform and AI-driven solutions, making advanced care accessible to everyone. Follow us @exoeffect on X, LinkedIn, Facebook, and Instagram.